OptoCeutics

Optoceutics operates in the medical-device and neurotechnology space, focusing on light-based sensory stimulation for brain health and cognitive wellness. Its EVY platform differentiates its product proposition through 40 Hz light stimulation and a multisensory approach that combines light and sound; EVY LIGHT® is specifically described as using patented Invisible Spectral Flicker technology. The company also presents its products as general wellness devices, rather than treatments for disease, an important distinction given its association with Alzheimer’s and dementia research. Its stated capabilities span therapeutic-device development and digital biomarkers, with an application intended to help users track progress. At the category level, Optoceutics sits among medical-device developers applying non-invasive stimulation to neurological health, where differentiation depends on device design, evidence quality, usability, and regulatory positioning. Four granted patents are recorded, alongside four registered trademarks. Those indicators suggest a technology and intellectual-property-led profile, but do not by themselves establish clinical efficacy, market adoption, or an advantage over other brain-stimulation approaches.

Founded in 2018, Optoceutics has developed from an early-stage neurotechnology company into a product-focused business centered on EVY LIGHT® and 40 Hz multisensory stimulation. Its documented funding history includes a €71,429 grant in January 2019, valued at $81,868, and non-equity assistance in March 2019 from SkyDeck Berkeley. A separate grant entry dated Dec 20, 2020 reports €4 million and says it enabled the hiring of two PhD candidates; the USD value is not established here. Patent activity provides another visible development marker: filings relating to gamma-stimulation light systems appeared from 2021 onward, followed by phototherapeutic-apparatus applications through 2024. The company is listed in the 11–50 employee band, although that broad range does not establish a growth trend. Its current leadership includes CEO Ngoc Mai Nguyen, CTO Marcus Carstensen, and co-founder Jes Broeng. Overall, the signals indicate a path from grant-supported research and team building toward product and intellectual-property development.